



# Very low mechanical index 2D and 3D contrast-echocardiography: dosages at the discretion of sonographers

Marina Choy, Alana Durand, Allen He, Riitta Paakkanen<sup>1</sup>, Victoria Sarban, Eila Mirhadi, Edith Pituskin<sup>2</sup>, Ian Paterson, Jonathan Choy, Harald Becher.  
 Alberta Mazankowski Heart Institute, University of Alberta Hospital, <sup>2</sup>Cross Cancer Institute, Edmonton, Canada. <sup>1</sup>Helsinki University Central Hospital, Helsinki, Finland.

## BACKGROUND

Contrast echocardiography has been widely used for the quantitative assessment of left ventricle (LV) ejection fraction in transthoracic echocardiography (TTE). The recommended dose for the bolus administration of DEFINITY® contrast agent is a single dose of 10 µL/kg (0.6 mL, 60 kg person) followed by a 10 mL saline flush with a second 10 µL/kg dose if needed.

Dosing schemes for contrast media were established by imaging methods which were less sensitive for the detection of contrast agents than the contrast specific imaging modalities used today.

## OBJECTIVE


The total contrast dosages were prospectively assessed in a large series of patients to provide benchmarks for contrast use with current state-of-the-art scanners in an echocardiography laboratory where sonographers administer the contrast agents.

## METHODS


Consecutive consenting patients (n=550) referred for contrast echocardiography for the monitoring of cardiotoxic effects of chemotherapy were included. All echocardiograms and contrast injections were performed mainly by two experienced sonographers. A Philips Epiq 7C ultrasound system with a X5-1 xMatrix array transducer (1.3-4.2 MHz) was used. All consenting patients received diluted DEFINITY prepared by diluting 0.5 mL DEFINITY into a 10 mL solution with saline. Bolus injections (0.5 mL) of diluted contrast were administered using a very low mechanical index (MI ≈ 0.10 – 0.18) contrast specific imaging modality in order to provide optimal LV delineation. Additional bolus injections were administered as needed for image optimization at the discretion of the sonographer. A minimum of two 2 beat loops of the apical four, two and three chamber views were acquired in all patients as well as 3D datasets. The total volume of undiluted DEFINITY used was recorded. The reading cardiologist reviewed the TTE studies.

## WORKFLOW



Informed consent





Intravenous initiation by sonographer/nurse



Non-contrast imaging



Contrast administration & imaging by same sonographer



Analysis




## RESULTS

550 patients received contrast during their echocardiograms (Figure 1). These echocardiograms were deemed diagnostic for quantitative assessment by the sonographer. No additional injections were requested by the reading cardiologist. The mean total volume of undiluted DEFINITY used was 0.3 mL ± 0.1 mL. The mode was 0.2 mL undiluted DEFINITY. In 98% of patients ≤ 0.5 mL of undiluted DEFINITY was used. No adverse reactions were reported.


There are still limitations to quality 3D contrast echocardiography which include poor temporal resolution, multi-beat acquisition requires patient to be able to hold breath, stitching artifact from motion or arrhythmia, apical destruction of contrast, mitral annulus identification due to edge shadowing, difficulty in optimizing orthogonal plane image quality due to rib shadows, LV axis alignment, and poor imaging windows.

A4 end diastole




104 mL

A4 end systole




40 mL

A2 end diastole




100 mL

A2 end systole



44 mL

Total volume of undiluted DEFINITY



## CONCLUSIONS

A comprehensive 2D and 3D contrast echocardiography study requires only low amounts of contrast agent when using very low MI contrast modalities on state-of-the-art scanners. This can be achieved when sonographers are allowed to decide on the level of contrast required based on image quality.

## REFERENCES

DEFINITY® [package insert]. N. Billerica, MA: Lantheus Medical Imaging; 2011.

## AUTHOR DISCLOSURES

Ian Paterson: Janssen Inc consultant  
 Jonathan Choy: Philips Healthcare Speakers' Bureau, Bracco Imaging Consultant  
 Harald Becher: Bracco Research Grant, Bracco Speakers' Bureau  
 No disclosures for other authors.

